New Herpes Drug Cuts Transmission by 94%: What the ABI-5366 Trial Results Mean for You

Category: MP News
Author: Kayla Cajilig-Bactung
Publication Date: June 5, 2026

For the first time in more than two decades, a new class of herpes treatment is showing results that could meaningfully change daily life for people living with HSV-2—and the science behind it is generating significant attention throughout the infectious disease community.

Assembly Biosciences, a California-based biotechnology company, recently announced Phase 1b clinical trial results showing its investigational drug ABI-5366 reduced HSV-2 viral shedding by 94% compared to placebo. The findings were presented as part of the company's ongoing clinical development program and could represent one of the most promising advances in herpes treatment in years.

The results are particularly noteworthy because viral shedding is the primary mechanism through which herpes simplex virus type 2 (HSV-2) is transmitted. Importantly, shedding can occur even when a person has no visible symptoms or active outbreaks.

What the Trial Actually Found

According to Assembly Biosciences, ABI-5366 achieved a 94% reduction in HSV-2 viral shedding during a 29-day evaluation period compared to placebo. This result exceeded the company's previously stated goal of achieving an 80% to 85% reduction in viral shedding.

The study also demonstrated a 94% reduction in genital lesion rates among participants receiving the treatment. While reducing transmission risk remains a primary objective, fewer lesions may also significantly improve quality of life for individuals managing recurrent herpes infections.

ABI-5366 belongs to a class of investigational drugs known as helicase-primase inhibitors. Unlike traditional antiviral therapies, which primarily suppress viral replication through established pathways, helicase-primase inhibitors target a different viral enzyme complex involved in HSV replication.

Researchers believe this alternative mechanism may offer advantages in efficacy, durability, and dosing convenience.

A Potential Shift Away from Daily Medication

Current antiviral medications such as valacyclovir are widely used to suppress outbreaks and reduce transmission risk. However, these medications generally require daily dosing to maintain effectiveness.

Assembly Biosciences reported that ABI-5366 demonstrated pharmacokinetic properties that may support once-weekly dosing and potentially even once-monthly dosing schedules in future studies.

If confirmed in larger clinical trials, this could represent a major convenience improvement for patients who currently rely on daily suppressive therapy.

The company also reported that the drug was generally well tolerated at doses up to 350 mg weekly, with no major safety concerns identified during the Phase 1b study.

A Second Experimental Herpes Drug Is Also Showing Promise

ABI-5366 is not the only herpes treatment candidate currently under development.

Assembly Biosciences also released data on ABI-1179, another investigational helicase-primase inhibitor. According to the company, ABI-1179 demonstrated a 98% reduction in HSV-2 shedding and a greater than 99% reduction in high viral-load shedding during its own Phase 1b evaluation.

Participants receiving a 50 mg weekly dose experienced a 91% reduction in virologically confirmed genital lesions.

Both ABI-5366 and ABI-1179 were featured at the 2026 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in Munich, Germany. ABI-1179's findings were selected as a late-breaker presentation, a designation typically reserved for especially significant or timely scientific developments.

What Happens Next?

Despite the encouraging results, experts caution that these treatments remain investigational.

ABI-5366 is expected to advance into Phase 2 clinical trials during 2026, where researchers will evaluate effectiveness and safety in a larger patient population over a longer period of time.

It is important to understand what these findings do—and do not—mean.

• These drugs are not cures for herpes.
• HSV remains a lifelong viral infection.
• The treatments have not yet received FDA approval.
• Additional clinical testing is required before they could become widely available.

Many promising therapies demonstrate strong early results but fail to replicate those outcomes during larger studies. Regulatory review and additional research remain necessary before any conclusions can be made regarding future approval.

Nevertheless, researchers note that a 94% reduction in viral shedding would represent a substantial improvement over current therapies if the results continue through later-stage trials.

Why This Matters for the Meet Positives Community

More than 500 million people worldwide are estimated to be living with HSV-2. While outbreaks and physical symptoms are often discussed, many people say the emotional challenges—including stigma, disclosure concerns, and dating anxiety—can be equally difficult.

A treatment capable of dramatically reducing transmission risk could potentially reshape how many individuals approach relationships and disclosure conversations.

For people navigating dating with herpes, advancements in treatment may help support more informed discussions while reducing some of the uncertainty that often surrounds transmission concerns.

Related resources:

• Herpes Dating
• STD Dating
• HIV Dating
• Herpes Disclosure: How, When, and What Real People Wish They Knew
• Join Meet Positives

Looking Ahead

The ABI-5366 and ABI-1179 programs represent some of the most promising herpes treatment developments in years. While additional studies are needed, the results have generated optimism among researchers, clinicians, and patient communities alike.

Meet Positives will continue monitoring the progress of both programs as they move through future clinical trials and regulatory review.

Sources

• Assembly Biosciences Phase 1b Clinical Trial Results (2026)
• European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Congress 2026
• Gilead Sciences Licensing Announcement
• FDA Clinical Trials and Drug Development Resources

Editor's Note

Clinical trial results are preliminary until confirmed through larger Phase 2 and Phase 3 studies. Meet Positives will continue monitoring future developments and update readers as new data becomes available.

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider regarding diagnosis, treatment decisions, or questions about HSV management.

Meet Positives is an editorially independent platform. This article was not sponsored or funded by Assembly Biosciences, Gilead Sciences, or any pharmaceutical company.